COVID-19 with baricitinib-induced symptomatic creatinine kinase elevation.

Abstract

Creatinine kinase elevation should be suspected if a patient receiving baricitinib for COVID-19 infection complains of myalgia during treatment, and the drug should be discontinued immediately.